TWD
SNDX icon

True Wealth Design’s Syndax Pharmaceuticals SNDX Stock Holding History

True Wealth Design’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.99K Sell
228
-33
-13% -$686 ﹤0.01% 1329
2026
Q1 		$6.1K Hold
261
– – ﹤0.01% 1134
2025
Q4 		$5.48K Buy
261
+52
+25% +$907 ﹤0.01% 1052
2025
Q3 		$3.22K Buy
209
+184
+736% +$2.41K ﹤0.01% 1278
2025
Q2 		$235 Sell
25
-72
-74% -$792 ﹤0.01% 2022
2025
Q1 		$1.19K Buy
97
+90
+1,286% +$1.27K ﹤0.01% 1202
2024
Q4 		$93 Buy
+7
New +$120 ﹤0.01% 1281

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

True Wealth Design's SNDX Position: Q2 2026 in Review

True Wealth Design reduced its Syndax Pharmaceuticals (SNDX) stake by 13% in Q2 2026, selling an estimated $686 and leaving 228 shares worth $4.99K. The position accounts for ﹤0.01% of the portfolio, ranked #1329.

True Wealth Design first reported a position in SNDX in Q4 2024 and has held it in 7 quarters since. The position peaked at $6.1K in Q1 2026. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • True Wealth Design held 228 shares of Syndax Pharmaceuticals worth $4.99K as of Q2 2026.
  • True Wealth Design sold 33 Syndax Pharmaceuticals shares in Q2 2026, an estimated $686.
  • Syndax Pharmaceuticals made up ﹤0.01% of True Wealth Design's portfolio in Q2 2026, its #1329 holding.
  • True Wealth Design first reported a position in Syndax Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • True Wealth Design's Syndax Pharmaceuticals position peaked at $6.1K in Q1 2026.
  • 242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on True Wealth Design's 13F filing for Q2 2026, filed 16 Jul 2026.